Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomised, Double-blind, Two-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Ixekizumab (SB35 and Taltz) in Healthy Participants

NCT07789964 is registered in ClinicalTrials.gov with Samsung Bioepis Co., Ltd. as lead sponsor.

NCT NCT07789964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07789964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomised, Double-blind, Two-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Ixekizumab (SB35 and Taltz) in Healthy Participants
Lead sponsor
Samsung Bioepis Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
September 4, 2026
Completion date
June 9, 2027
Enrollment
174 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy